magnesium hydroxide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
4244 1309-42-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • magnesium hydroxide
An inorganic compound that occurs in nature as the mineral brucite. It acts as an antacid with cathartic effects.
  • Molecular weight: 58.32
  • Formula: H2MgO2
  • CLOGP: -1.75
  • LIPINSKI: None
  • HAC: 2
  • HDO: 2
  • TPSA: 40.46
  • ALOGS:
  • ROTB: 0

Drug dosage:

DoseUnitRoute
3 g O
0.50 g O

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Oct. 16, 2000 FDA MCNEIL CONS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sedation complication 513.37 10.88 220 46893 8546 50549465
Creatinine renal clearance decreased 461.38 10.88 224 46889 11657 50546354
Cognitive disorder 439.81 10.88 349 46764 43774 50514237
Orthostatic hypotension 431.38 10.88 294 46819 29187 50528824
Sedation 419.03 10.88 293 46820 30317 50527694
Blood calcium decreased 387.54 10.88 241 46872 20465 50537546
Balance disorder 327.47 10.88 365 46748 70225 50487786
Toxicity to various agents 318.44 10.88 646 46467 211853 50346158
Infusion related reaction 252.01 10.88 514 46599 169043 50388968
Hypotension 235.12 10.88 610 46503 234859 50323152
Depressed level of consciousness 229.51 10.88 262 46851 51691 50506320
Blood pressure fluctuation 211.93 10.88 211 46902 35612 50522399
Rheumatoid arthritis 210.65 10.88 533 46580 202017 50355994
Mobility decreased 176.61 10.88 288 46825 79660 50478351
Blood pressure increased 146.26 10.88 358 46755 132774 50425237
Temperature regulation disorder 135.48 10.88 70 47043 4157 50553854
Heart rate decreased 133.08 10.88 167 46946 36330 50521681
Macular degeneration 130.91 10.88 108 47005 14280 50543731
Immunodeficiency 119.91 10.88 104 47009 14724 50543287
Electric shock 114.03 10.88 41 47072 987 50557024
Drug abuse 112.83 10.88 201 46912 59645 50498366
Throat irritation 109.65 10.88 138 46975 30101 50527910
Blood pressure systolic increased 101.28 10.88 144 46969 35305 50522706
Food allergy 100.01 10.88 73 47040 8064 50549947
Blood pressure systolic abnormal 98.96 10.88 71 47042 7635 50550376
Constipation 94.99 10.88 383 46730 185325 50372686
Blood pressure diastolic abnormal 90.91 10.88 73 47040 9288 50548723
Coeliac disease 89.21 10.88 70 47043 8615 50549396
Fall 86.97 10.88 571 46542 334361 50223650
Oxygen saturation decreased 85.74 10.88 202 46911 73046 50484965
Intervertebral discitis 79.45 10.88 42 47071 2614 50555397
Blood pressure diastolic decreased 72.97 10.88 84 47029 16697 50541314
Heart rate increased 72.59 10.88 196 46917 77054 50480957
Maternal exposure during pregnancy 72.49 10.88 29 47084 159749 50398262
Pain 68.26 10.88 830 46283 578073 49979938
Post-traumatic stress disorder 65.46 10.88 44 47069 4259 50553752
Smear cervix abnormal 56.61 10.88 34 47079 2707 50555304
Systemic lupus erythematosus 55.37 10.88 31 47082 140591 50417420
Drug interaction 48.63 10.88 69 47044 199552 50358459
Demyelination 48.17 10.88 42 47071 5984 50552027
Bursitis 46.47 10.88 78 47035 22057 50535954
Weight increased 45.63 10.88 333 46780 201558 50356453
Hyperhidrosis 44.49 10.88 183 46930 89243 50468768
Cataract 44.40 10.88 120 46993 47180 50510831
Product dose omission issue 44.32 10.88 64 47049 183774 50374237
Rash erythematous 43.93 10.88 99 47014 34753 50523258
Glossodynia 43.34 10.88 27 47086 115542 50442469
Adrenal insufficiency 42.36 10.88 59 47054 14184 50543827
Ulcer 42.16 10.88 71 47042 20129 50537882
Alopecia 41.05 10.88 106 47007 244941 50313070
Temperature intolerance 40.17 10.88 42 47071 7497 50550514
Progressive multifocal leukoencephalopathy 37.93 10.88 50 47063 11407 50546604
Injection site pain 37.56 10.88 29 47084 110995 50447016
Respiratory rate increased 36.64 10.88 49 47064 11336 50546675
Gastric disorder 36.20 10.88 83 47030 29465 50528546
Gangrene 36.10 10.88 32 47081 4660 50553351
Arterial occlusive disease 35.43 10.88 32 47081 4776 50553235
Multiple sclerosis 35.01 10.88 66 47047 20427 50537584
Injection site erythema 34.96 10.88 13 47100 74923 50483088
Tooth disorder 34.15 10.88 72 47041 24156 50533855
Coordination abnormal 33.14 10.88 47 47066 11487 50546524
Acute kidney injury 32.12 10.88 107 47006 227951 50330060
Arthralgia 31.80 10.88 579 46534 438123 50119888
Herpes zoster 31.45 10.88 140 46973 70646 50487365
Diarrhoea 30.64 10.88 376 46737 588100 49969911
Skin fissures 30.52 10.88 39 47074 8629 50549382
Exposure during pregnancy 29.27 10.88 42 47071 120973 50437038
Arthritis 28.88 10.88 158 46955 86563 50471448
Dry mouth 28.75 10.88 116 46997 56062 50501949
Joint injury 28.70 10.88 63 47050 21726 50536285
Nasopharyngitis 28.68 10.88 290 46823 192637 50365374
Weight decreased 28.44 10.88 323 46790 220922 50337089
Pemphigus 27.81 10.88 43 47070 120123 50437888
Pericarditis 27.32 10.88 20 47093 78669 50479342
Nail bed inflammation 26.83 10.88 11 47102 381 50557630
Anticholinergic syndrome 26.46 10.88 18 47095 1777 50556234
Hypermagnesaemia 26.35 10.88 14 47099 880 50557131
Hand deformity 26.03 10.88 33 47080 100166 50457845
Cystic fibrosis pancreatic 26.00 10.88 7 47106 61 50557950
Ear pruritus 25.17 10.88 20 47093 2506 50555505
Dyspnoea 25.15 10.88 359 46754 547249 50010762
Cardiac failure 24.30 10.88 21 47092 76019 50481992
Endodontic procedure 23.70 10.88 20 47093 2726 50555285
Laryngitis 23.52 10.88 39 47074 10917 50547094
Body temperature decreased 22.27 10.88 48 47065 16347 50541664
Neuralgia 22.07 10.88 57 47056 21806 50536205
Fluid retention 21.61 10.88 99 47014 50550 50507461
General physical health deterioration 21.31 10.88 65 47048 142369 50415642
Localised infection 21.30 10.88 62 47051 25423 50532588
Condition aggravated 21.13 10.88 176 46937 296882 50261129
Death 20.85 10.88 198 46915 325181 50232830
Excessive skin 20.78 10.88 7 47106 138 50557873
Wrong technique in product usage process 20.75 10.88 13 47100 55497 50502514
Injection site extravasation 20.72 10.88 30 47083 7471 50550540
Therapeutic response decreased 20.66 10.88 93 47020 47138 50510873
Muscle injury 19.89 10.88 5 47108 37106 50520905
Anti-cyclic citrullinated peptide antibody positive 19.66 10.88 22 47091 70565 50487446
Flushing 19.62 10.88 118 46995 66897 50491114
Sleep disorder due to general medical condition, insomnia type 19.45 10.88 3 47110 31444 50526567
C-reactive protein increased 19.43 10.88 117 46996 66357 50491654
Erythema 19.35 10.88 215 46898 146199 50411812
Periorbital swelling 19.00 10.88 15 47098 1862 50556149
Anti-cyclic citrullinated peptide antibody 18.92 10.88 14 47099 1578 50556433
Vomiting 18.76 10.88 309 46804 460449 50097562
Cough 18.69 10.88 322 46791 240942 50317069
Wound 18.27 10.88 45 47068 105749 50452262
Abortion spontaneous 18.25 10.88 8 47105 41764 50516247
Irritable bowel syndrome 17.95 10.88 13 47100 51428 50506583
Pregnancy 17.89 10.88 3 47110 29574 50528437
Occult blood 17.54 10.88 12 47101 1195 50556816
Ocular procedural complication 17.30 10.88 8 47105 372 50557639
Heliotrope rash 17.28 10.88 6 47107 130 50557881
Fumbling 16.86 10.88 6 47107 140 50557871
Nose deformity 16.74 10.88 6 47107 143 50557868
Gastrointestinal toxicity 16.40 10.88 21 47092 4656 50553355
Therapy non-responder 16.34 10.88 92 47021 50930 50507081
Treatment noncompliance 16.28 10.88 4 47109 30146 50527865
Allergy to plants 16.27 10.88 9 47104 613 50557398
Tongue disorder 16.14 10.88 30 47083 9186 50548825
Joint swelling 16.08 10.88 319 46794 244967 50313044
Foetal exposure during pregnancy 16.06 10.88 3 47110 27356 50530655
Poikiloderma 16.00 10.88 6 47107 163 50557848
Vein collapse 15.97 10.88 9 47104 636 50557375
Endometrial disorder 15.85 10.88 9 47104 645 50557366
Injection site pruritus 15.76 10.88 9 47104 40402 50517609
Rash 15.69 10.88 300 46813 437171 50120840
Confusional state 15.66 10.88 105 47008 185823 50372188
No adverse event 15.36 10.88 6 47107 33572 50524439
Intensive care unit acquired weakness 15.32 10.88 9 47104 688 50557323
Pulmonary toxicity 15.01 10.88 22 47091 5540 50552471
Toothache 14.99 10.88 42 47071 16852 50541159
Folliculitis 14.92 10.88 9 47104 39216 50518795
Renal impairment 14.85 10.88 30 47083 75631 50482380
Drug-induced liver injury 14.65 10.88 4 47109 28091 50529920
Paraesthesia 14.55 10.88 60 47053 120183 50437828
Adverse drug reaction 14.53 10.88 18 47095 55204 50502807
Cholestasis 14.46 10.88 3 47110 25398 50532613
Loss of personal independence in daily activities 14.42 10.88 27 47086 70023 50487988
Back pain 14.36 10.88 286 46827 219744 50338267
Off label use 14.19 10.88 335 46778 474091 50083920
Iron deficiency 14.13 10.88 22 47091 5840 50552171
Inflammation 14.06 10.88 96 47017 56816 50501195
Injection site swelling 14.01 10.88 11 47102 41762 50516249
Nerve compression 13.96 10.88 25 47088 7437 50550574
Mechanical urticaria 13.96 10.88 7 47106 390 50557621
Inappropriate schedule of product administration 13.66 10.88 29 47084 71802 50486209
Wheezing 13.60 10.88 23 47090 62024 50495987
Vein rupture 13.50 10.88 9 47104 859 50557152
Ill-defined disorder 13.39 10.88 92 47021 54562 50503449
Therapy cessation 13.02 10.88 4 47109 26007 50532004
Thrombocytopenia 12.92 10.88 68 47045 127605 50430406
Blood pressure diastolic increased 12.75 10.88 24 47089 7419 50550592
Dysphagia 12.71 10.88 119 46994 77399 50480612
Scratch 12.49 10.88 19 47094 4943 50553068
Lip blister 12.38 10.88 12 47101 1957 50556054
Myocardial infarction 12.35 10.88 42 47071 88985 50469026
Hyponatraemia 12.25 10.88 47 47066 96092 50461919
White blood cells urine positive 12.20 10.88 18 47095 4560 50553451
Swelling 12.10 10.88 124 46989 200748 50357263
Noninfective encephalitis 11.97 10.88 6 47107 334 50557677
Enterococcus test positive 11.78 10.88 9 47104 1065 50556946
Benign vaginal neoplasm 11.73 10.88 4 47109 82 50557929
Dust allergy 11.68 10.88 7 47106 555 50557456
Abdominal discomfort 11.61 10.88 149 46964 231492 50326519
Oropharyngeal pain 11.56 10.88 117 46996 77684 50480327
Cystitis 11.51 10.88 76 47037 44488 50513523
Injection site reaction 11.47 10.88 18 47095 50014 50507997
Myelopathy 11.43 10.88 13 47100 2548 50555463
Psoriasis 11.41 10.88 30 47083 68970 50489041
Lupus endocarditis 11.34 10.88 5 47108 208 50557803
Viral upper respiratory tract infection 11.29 10.88 22 47091 6974 50551037
Hepatocellular injury 11.29 10.88 5 47108 25942 50532069
Lower respiratory tract infection 11.21 10.88 48 47065 95153 50462858
Premature delivery 11.21 10.88 4 47109 23659 50534352
Swelling face 11.07 10.88 20 47093 52575 50505436
Malignant neoplasm progression 10.98 10.88 30 47083 68094 50489917
Synovitis 10.90 10.88 69 47044 123796 50434215

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Toxicity to various agents 207.55 12.73 358 16225 173303 29384641
Drug abuse 147.80 12.73 202 16381 79681 29478263
Infusion related reaction 114.68 12.73 132 16451 43754 29514190
Oxygen saturation decreased 74.59 12.73 108 16475 44829 29513115
Blood pressure increased 73.54 12.73 141 16442 73662 29484282
Blood pressure fluctuation 62.58 12.73 66 16517 19828 29538116
Heart rate decreased 61.79 12.73 73 16510 24839 29533105
Rheumatoid arthritis 45.82 12.73 72 16511 32080 29525864
Blood pressure diastolic decreased 30.88 12.73 28 16555 6994 29550950
Blood pressure systolic increased 30.15 12.73 42 16541 16803 29541141
Nasopharyngitis 29.69 12.73 87 16496 59578 29498366
Blood pressure diastolic abnormal 29.02 12.73 18 16565 2533 29555411
Device breakage 27.02 12.73 15 16568 1719 29556225
Arthralgia 23.42 12.73 146 16437 139471 29418473
Clumsiness 23.39 12.73 13 16570 1493 29556451
Normochromic normocytic anaemia 23.16 12.73 18 16565 3640 29554304
Hypermagnesaemia 21.78 12.73 7 16576 201 29557743
Constipation 20.15 12.73 121 16462 114039 29443905
Hernia 19.90 12.73 24 16559 8334 29549610
Perineal pain 18.64 12.73 9 16574 773 29557171
Supraventricular tachycardia 18.22 12.73 25 16558 9859 29548085
Pemphigus 17.92 12.73 10 16573 1158 29556786
Granulomatosis with polyangiitis 17.38 12.73 9 16574 897 29557047
Red cell distribution width increased 17.31 12.73 17 16566 4690 29553254
Unresponsive to stimuli 16.91 12.73 41 16542 25085 29532859
Blood pressure diastolic increased 16.80 12.73 15 16568 3671 29554273
Blood pressure systolic abnormal 16.73 12.73 12 16571 2149 29555795
Environmental exposure 16.30 12.73 6 16577 261 29557683
Phlebosclerosis 15.48 12.73 5 16578 146 29557798
Haematocrit decreased 15.08 12.73 43 16540 28979 29528965
Heart rate increased 14.99 12.73 52 16531 38886 29519058
Drug interaction 14.64 12.73 59 16524 197326 29360618
Antineutrophil cytoplasmic antibody positive 14.46 12.73 7 16576 604 29557340
Musculoskeletal disorder 14.06 12.73 16 16567 5224 29552720
Body temperature decreased 13.97 12.73 23 16560 10641 29547303
Rhinitis 13.52 12.73 15 16568 4763 29553181
Sleep apnoea syndrome 13.24 12.73 30 16553 17569 29540375
Dysphagia 12.92 12.73 63 16520 54863 29503081

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sedation complication 546.99 11.12 236 55188 10118 64433190
Creatinine renal clearance decreased 478.19 11.12 238 55186 14183 64429125
Toxicity to various agents 472.04 11.12 993 54431 362520 64080788
Cognitive disorder 443.21 11.12 372 55052 54715 64388593
Infusion related reaction 429.79 11.12 613 54811 163854 64279454
Blood calcium decreased 392.74 11.12 255 55169 25299 64418009
Sedation 392.64 11.12 308 55116 41154 64402154
Orthostatic hypotension 358.22 11.12 307 55117 46431 64396877
Rheumatoid arthritis 353.02 11.12 559 54865 163735 64279573
Balance disorder 317.84 11.12 376 55048 83550 64359758
Blood pressure fluctuation 257.78 11.12 268 55156 51603 64391705
Blood pressure increased 227.26 11.12 475 54949 172077 64271231
Drug abuse 212.45 11.12 396 55028 131978 64311330
Depressed level of consciousness 198.44 11.12 294 55130 81142 64362166
Mobility decreased 195.11 11.12 300 55124 85540 64357768
Heart rate decreased 190.87 11.12 236 55188 54831 64388477
Hypotension 189.15 11.12 736 54688 380238 64063070
Pain 149.96 11.12 898 54526 552613 63890695
Oxygen saturation decreased 142.06 11.12 296 55128 106880 64336428
Temperature regulation disorder 138.07 11.12 69 55355 4142 64439166
Blood pressure systolic increased 122.51 11.12 180 55244 49273 64394035
Throat irritation 117.86 11.12 143 55281 32568 64410740
Blood pressure diastolic abnormal 115.91 11.12 90 55334 11827 64431481
Blood pressure systolic abnormal 114.31 11.12 83 55341 9859 64433449
Immunodeficiency 113.56 11.12 101 55323 16023 64427285
Electric shock 106.04 11.12 39 55385 1090 64442218
Food allergy 105.26 11.12 72 55352 7779 64435529
Constipation 103.06 11.12 430 54994 228907 64214401
Coeliac disease 101.81 11.12 69 55355 7343 64435965
Blood pressure diastolic decreased 101.46 11.12 110 55314 22191 64421117
Drug interaction 86.09 11.12 111 55313 361972 64081336
Heart rate increased 82.50 11.12 228 55196 98447 64344861
Fall 80.10 11.12 622 54802 416204 64027104
Acute kidney injury 77.04 11.12 170 55254 449070 63994238
Arthralgia 72.13 11.12 636 54788 441624 64001684
Intervertebral discitis 67.98 11.12 42 55382 3815 64439493
Nasopharyngitis 64.67 11.12 336 55088 195737 64247571
Post-traumatic stress disorder 64.65 11.12 42 55382 4163 64439145
Smear cervix abnormal 63.71 11.12 34 55390 2340 64440968
Cataract 61.44 11.12 136 55288 51126 64392182
Weight increased 59.91 11.12 350 55074 212998 64230310
Tooth disorder 49.02 11.12 77 55347 22325 64420983
Bursitis 48.62 11.12 75 55349 21410 64421898
Demyelination 44.56 11.12 41 55383 6793 64436515
Respiratory rate increased 44.33 11.12 66 55358 18265 64425043
Hyperhidrosis 43.90 11.12 218 55206 124702 64318606
Multiple sclerosis 41.30 11.12 65 55359 18876 64424432
Condition aggravated 40.81 11.12 173 55251 372253 64071055
Diarrhoea 40.77 11.12 411 55013 722293 63721015
Product dose omission issue 39.11 11.12 67 55357 194680 64248628
Hypermagnesaemia 39.01 11.12 19 55405 1078 64442230
Cardiac failure 38.75 11.12 34 55390 132339 64310969
Joint swelling 38.28 11.12 316 55108 215066 64228242
Temperature intolerance 38.03 11.12 41 55383 8214 64435094
Rash erythematous 37.33 11.12 109 55315 48524 64394784
Herpes zoster 35.89 11.12 149 55275 79038 64364270
Gastric disorder 35.59 11.12 78 55346 29119 64414189
Injection site erythema 32.81 11.12 10 55414 70790 64372518
Drug reaction with eosinophilia and systemic symptoms 32.79 11.12 4 55420 54213 64389095
Ulcer 32.19 11.12 65 55359 22925 64420383
Coordination abnormal 32.14 11.12 51 55373 14913 64428395
Localised infection 31.70 11.12 76 55348 30085 64413223
Gangrene 31.30 11.12 35 55389 7303 64436005
General physical health deterioration 31.27 11.12 82 55342 204343 64238965
Weight decreased 31.22 11.12 379 55045 285360 64157948
Arterial occlusive disease 30.78 11.12 34 55390 6999 64436309
Skin fissures 30.70 11.12 41 55383 10265 64433043
Body temperature decreased 30.17 11.12 68 55356 25860 64417448
Injection site pain 29.82 11.12 31 55393 111377 64331931
Therapeutic response decreased 28.36 11.12 104 55320 52084 64391224
Back pain 28.27 11.12 334 55090 249837 64193471
Maternal exposure during pregnancy 27.61 11.12 25 55399 95859 64347449
Neuralgia 27.54 11.12 66 55358 26118 64417190
Adrenal insufficiency 27.32 11.12 60 55364 22427 64420881
Laryngitis 27.08 11.12 40 55384 10991 64432317
Cystic fibrosis pancreatic 26.56 11.12 7 55417 61 64443247
Blood pressure diastolic increased 24.98 11.12 38 55386 10714 64432594
Dry mouth 24.54 11.12 110 55314 60308 64383000
Endodontic procedure 23.58 11.12 18 55406 2305 64441003
Myocardial infarction 23.50 11.12 69 55355 165752 64277556
Anticholinergic syndrome 23.47 11.12 19 55405 2650 64440658
Cholestasis 23.36 11.12 5 55419 44867 64398441
Flushing 23.32 11.12 131 55293 78517 64364791
Ill-defined disorder 23.28 11.12 87 55337 43965 64399343
Arthritis 23.15 11.12 137 55287 83677 64359631
Progressive multifocal leukoencephalopathy 22.55 11.12 49 55375 18183 64425125
Injection site extravasation 22.31 11.12 31 55393 8055 64435253
Excessive skin 21.97 11.12 7 55417 125 64443183
Anti-cyclic citrullinated peptide antibody 21.73 11.12 14 55410 1368 64441940
Ear pruritus 21.43 11.12 18 55406 2642 64440666
Nail bed inflammation 21.15 11.12 10 55414 531 64442777
Dysphagia 20.74 11.12 160 55264 106652 64336656
Vein rupture 20.33 11.12 14 55410 1529 64441779
Eosinophilia 20.32 11.12 4 55420 38072 64405236
Allergy to plants 20.10 11.12 10 55414 594 64442714
Periorbital swelling 20.07 11.12 15 55409 1861 64441447
Renal impairment 20 11.12 55 55369 134962 64308346
Drug-induced liver injury 19.89 11.12 8 55416 47635 64395673
Rhabdomyolysis 19.86 11.12 30 55394 91696 64351612
Upper respiratory tract infection 19.48 11.12 118 55306 72667 64370641
Dyspnoea 19.43 11.12 470 54954 718204 63725104
Thrombocytopenia 19.28 11.12 113 55311 223688 64219620
Musculoskeletal stiffness 18.86 11.12 175 55249 123031 64320277
Fluid retention 18.82 11.12 101 55323 59505 64383803
Endometrial disorder 18.62 11.12 9 55415 502 64442806
Granulomatosis with polyangiitis 18.45 11.12 15 55409 2105 64441203
Hyperkalaemia 18.33 11.12 37 55387 101092 64342216
Hepatocellular injury 18.23 11.12 8 55416 45227 64398081
Haematemesis 17.88 11.12 9 55415 46990 64396318
Heliotrope rash 17.75 11.12 6 55418 130 64443178
Multiple organ dysfunction syndrome 17.63 11.12 38 55386 101375 64341933
Fumbling 17.62 11.12 6 55418 133 64443175
Anaemia 17.11 11.12 226 55198 378454 64064854
Tubulointerstitial nephritis 17.02 11.12 3 55421 30906 64412402
Occult blood 16.79 11.12 12 55412 1390 64441918
Nose deformity 16.69 11.12 6 55418 157 64443151
Body temperature increased 16.61 11.12 69 55355 36597 64406711
Vein collapse 16.59 11.12 9 55415 640 64442668
Ocular procedural complication 16.47 11.12 8 55416 451 64442857
Joint effusion 16.42 11.12 36 55388 13437 64429871
Toothache 16.25 11.12 42 55382 17417 64425891
Hypoglycaemia 16.20 11.12 33 55391 89859 64353449
Death 16.12 11.12 305 55119 482400 63960908
Confusional state 15.70 11.12 146 55278 260998 64182310
Sinusitis 15.66 11.12 193 55231 145735 64297573
Poikiloderma 15.63 11.12 7 55417 328 64442980
Tongue disorder 15.55 11.12 33 55391 12047 64431261
Perineal pain 15.38 11.12 10 55414 993 64442315
Mechanical urticaria 15.18 11.12 7 55417 351 64442957
Environmental exposure 15.18 11.12 7 55417 351 64442957
Erythema 15.04 11.12 235 55189 186835 64256473
Hyponatraemia 14.95 11.12 71 55353 148268 64295040
Off label use 14.92 11.12 422 55002 632384 63810924
Osteonecrosis of jaw 14.60 11.12 8 55416 39817 64403491
Loss of personal independence in daily activities 14.46 11.12 25 55399 72429 64370879
Systemic lupus erythematosus 14.41 11.12 28 55396 77584 64365724
Loss of consciousness 14.38 11.12 72 55352 148293 64295015
Diabetic ketoacidosis 14.22 11.12 4 55420 29841 64413467
Cystitis 13.94 11.12 73 55351 42602 64400706
Cough 13.94 11.12 349 55075 301799 64141509
Rash maculo-papular 13.85 11.12 12 55412 47014 64396294
Hot flush 13.69 11.12 77 55347 46158 64397150
Joint injury 13.55 11.12 47 55377 22900 64420408
Circulatory collapse 13.54 11.12 6 55418 33726 64409582
Oropharyngeal pain 13.48 11.12 126 55298 88741 64354567
Epilepsy 13.40 11.12 6 55418 33525 64409783
Phlebosclerosis 13.39 11.12 5 55419 146 64443162
Lactic acidosis 13.38 11.12 20 55404 61390 64381918
Inappropriate schedule of product administration 13.36 11.12 38 55386 92248 64351060
Injection site pruritus 13.29 11.12 8 55416 37818 64405490
No adverse event 13.29 11.12 4 55420 28557 64414751
Glossodynia 13.21 11.12 22 55402 64674 64378634
Psoriasis 13.19 11.12 26 55398 71677 64371631
Swelling face 13.15 11.12 19 55405 59147 64384161
Pericarditis 13.01 11.12 21 55403 62495 64380813
Irritable bowel syndrome 13.00 11.12 8 55416 37361 64405947
Treatment noncompliance 12.92 11.12 11 55413 43471 64399837
Myoclonus 12.67 11.12 3 55421 25115 64418193
Neuroleptic malignant syndrome 12.58 11.12 3 55421 24993 64418315
Renal failure 12.52 11.12 98 55326 181590 64261718
Aspartate aminotransferase increased 12.26 11.12 57 55367 119731 64323577
Fatigue 12.23 11.12 772 54652 747958 63695350
Dental caries 12.20 11.12 28 55396 10772 64432536
Benign vaginal neoplasm 12.13 11.12 4 55420 80 64443228
Melaena 12.09 11.12 17 55407 53531 64389777
Lip blister 11.80 11.12 12 55412 2247 64441061
Clumsiness 11.76 11.12 13 55411 2678 64440630
Accidental exposure to product 11.72 11.12 4 55420 26360 64416948
Injection site swelling 11.64 11.12 11 55413 41342 64401966
Intervertebral disc degeneration 11.63 11.12 31 55393 13089 64430219
Blood lactate dehydrogenase increased 11.62 11.12 7 55417 33071 64410237
Wrong technique in product usage process 11.58 11.12 24 55400 64950 64378358
Alanine aminotransferase increased 11.54 11.12 71 55353 138960 64304348
Malignant neoplasm progression 11.38 11.12 54 55370 112817 64330491
Pancreatitis acute 11.38 11.12 12 55412 42843 64400465
Creatinine urine increased 11.17 11.12 6 55418 418 64442890
Vessel puncture site bruise 11.17 11.12 6 55418 418 64442890
Sleep apnoea syndrome 11.14 11.12 53 55371 29779 64413529

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A02AA04 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR ACID RELATED DISORDERS
ANTACIDS
Magnesium compounds
ATC G04BX01 GENITO URINARY SYSTEM AND SEX HORMONES
UROLOGICALS
UROLOGICALS
Other urologicals
MeSH PA D000863 Antacids
MeSH PA D005765 Gastrointestinal Agents
CHEBI has role CHEBI:65265 antacids
CHEBI has role CHEBI:79314 flame retardants

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Peptic ulcer indication 13200003 DOID:750
Constipation indication 14760008 DOID:2089
Heartburn indication 16331000
Indigestion indication 162031009
Gastroesophageal reflux disease indication 235595009 DOID:8534
Incomplete passage of stool indication 249515001
Gastric Hypersecretory Conditions indication
Heartburn Prevention indication
Hiatal Hernia with Reflux Esophagitis indication
Hypocalcemia off-label use 5291005
Upper gastrointestinal hemorrhage off-label use 37372002
Duodenal ulcer disease off-label use 51868009 DOID:1724
Zollinger-Ellison syndrome off-label use 53132006 DOID:0050782
Multiple endocrine adenomas off-label use 60549007
Osteoporosis off-label use 64859006 DOID:11476
Postmenopausal osteoporosis off-label use 102447009
Systemic mast cell disease off-label use 397016004 DOID:349
Gastric ulcer off-label use 397825006 DOID:10808
Prevention of Stress Ulcer off-label use
Stress-Related GI Mucosal Bleeding Prevention off-label use
Maintenance of Healing Duodenal Ulcer off-label use
Renal Osteodystrophy with Hyperphosphatemia off-label use
Dyspepsia Prevention off-label use
Hypophosphatemia contraindication 4996001
Sarcoidosis contraindication 31541009 DOID:11335
Dehydration contraindication 34095006
Fecal impaction contraindication 44635007
Diarrhea contraindication 62315008
Hypercalcemia contraindication 66931009 DOID:12678
Hypermagnesemia contraindication 66978005
Hyperparathyroidism contraindication 66999008 DOID:13543
Hemorrhoids contraindication 70153002 DOID:9746
Appendicitis contraindication 74400008 DOID:8337
Kidney disease contraindication 90708001 DOID:557
Kidney stone contraindication 95570007
Gastrointestinal obstruction contraindication 126765001
Impaired renal function disorder contraindication 197663003
Osteolysis contraindication 203522001
Disease of liver contraindication 235856003 DOID:409
Chronic diarrhea contraindication 236071009
Aluminum intoxication contraindication 236546003
Malignant tumor of stomach contraindication 363349007 DOID:10534




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4017693 VUID
N0000146067 NUI
D00731 KEGG_DRUG
4017693 VANDF
C0024476 UMLSCUI
CHEBI:6637 CHEBI
CHEMBL1200718 ChEMBL_ID
D008276 MESH_DESCRIPTOR_UI
DB09104 DRUGBANK_ID
NBZ3QY004S UNII
73981 PUBCHEM_CID
6581 RXNORM
5013 MMSL
5579 MMSL
d00982 MMSL
001119 NDDF
001186 NDDF
387337001 SNOMEDCT_US
60468008 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Milk of Magnesia HUMAN OTC DRUG LABEL 1 0054-3567 CONCENTRATE 2400 mg ORAL OTC monograph not final 10 sections
Good Sense Dual Action Complete HUMAN OTC DRUG LABEL 3 0113-0032 TABLET, CHEWABLE 165 mg ORAL ANDA 15 sections
Good Sense Dual Action Complete HUMAN OTC DRUG LABEL 3 0113-0032 TABLET, CHEWABLE 165 mg ORAL ANDA 15 sections
good sense milk of magnesiastimulant free HUMAN OTC DRUG LABEL 1 0113-0332 SUSPENSION 1200 mg ORAL OTC monograph not final 14 sections
good sense milk of magnesiastimulant free HUMAN OTC DRUG LABEL 1 0113-0332 SUSPENSION 1200 mg ORAL OTC monograph not final 14 sections
Good Sense antacid HUMAN OTC DRUG LABEL 3 0113-0340 SUSPENSION 800 mg ORAL OTC monograph final 13 sections
Good Sense antacid HUMAN OTC DRUG LABEL 3 0113-0340 SUSPENSION 800 mg ORAL OTC monograph final 13 sections
Good Sense AntacidRegular Strength HUMAN OTC DRUG LABEL 3 0113-0357 SUSPENSION 400 mg ORAL OTC monograph final 13 sections
Good Sense AntacidRegular Strength HUMAN OTC DRUG LABEL 3 0113-0357 SUSPENSION 400 mg ORAL OTC monograph final 13 sections
Good Sense milk of magnesiastimulant free HUMAN OTC DRUG LABEL 1 0113-0396 SUSPENSION 1200 mg ORAL OTC monograph not final 14 sections
Good Sense milk of magnesiastimulant free HUMAN OTC DRUG LABEL 1 0113-0396 SUSPENSION 1200 mg ORAL OTC monograph not final 14 sections
Good Sense AntacidMaximum Strength HUMAN OTC DRUG LABEL 3 0113-0588 SUSPENSION 800 mg ORAL OTC monograph final 13 sections
Good Sense AntacidMaximum Strength HUMAN OTC DRUG LABEL 3 0113-0588 SUSPENSION 800 mg ORAL OTC monograph final 13 sections
good sense antacid HUMAN OTC DRUG LABEL 3 0113-0851 SUSPENSION 400 mg ORAL OTC monograph final 13 sections
good sense antacid HUMAN OTC DRUG LABEL 3 0113-0851 SUSPENSION 400 mg ORAL OTC monograph final 13 sections
Good Sense Milk of Magnesia HUMAN OTC DRUG LABEL 1 0113-0949 SUSPENSION 1200 mg ORAL OTC monograph not final 14 sections
Good Sense Milk of Magnesia HUMAN OTC DRUG LABEL 1 0113-0949 SUSPENSION 1200 mg ORAL OTC monograph not final 14 sections
basic care dual action complete HUMAN OTC DRUG LABEL 3 0113-7321 TABLET, CHEWABLE 165 mg ORAL ANDA 15 sections
basic care dual action complete HUMAN OTC DRUG LABEL 3 0113-7321 TABLET, CHEWABLE 165 mg ORAL ANDA 15 sections
basic care milk of magnesia HUMAN OTC DRUG LABEL 1 0113-7332 SUSPENSION 1200 mg ORAL OTC monograph not final 14 sections
basic care milk of magnesia HUMAN OTC DRUG LABEL 1 0113-7332 SUSPENSION 1200 mg ORAL OTC monograph not final 14 sections
Milk of Magnesia HUMAN OTC DRUG LABEL 1 0121-0431 SUSPENSION 400 mg ORAL OTC monograph final 15 sections
Milk of Magnesia HUMAN OTC DRUG LABEL 1 0121-0431 SUSPENSION 400 mg ORAL OTC monograph final 15 sections
MILK OF MAGNESIA HUMAN OTC DRUG LABEL 1 0121-0527 SUSPENSION 2400 mg ORAL OTC monograph final 16 sections
MILK OF MAGNESIA HUMAN OTC DRUG LABEL 1 0121-0527 SUSPENSION 2400 mg ORAL OTC monograph final 16 sections
Milk of Magnesia Concentrate HUMAN OTC DRUG LABEL 1 0121-0940 SUSPENSION 2400 mg ORAL OTC monograph final 16 sections
Milk of Magnesia Concentrate HUMAN OTC DRUG LABEL 1 0121-0940 SUSPENSION 2400 mg ORAL OTC monograph final 16 sections
Mag-AL Liquid HUMAN OTC DRUG LABEL 2 0121-1760 SUSPENSION 200 mg ORAL OTC monograph final 14 sections
Mag-AL Liquid HUMAN OTC DRUG LABEL 2 0121-1760 SUSPENSION 200 mg ORAL OTC monograph final 14 sections
Mag-AL Plus HUMAN OTC DRUG LABEL 3 0121-1761 SUSPENSION 200 mg ORAL OTC monograph final 14 sections